泰恩康：控股子公司CKBA乳膏申报儿童白癜风获药物临床试验批准通知书

Core Viewpoint - The company Tianenkang (301263) announced that its subsidiary, Bochuangyuan, has received approval from the National Medical Products Administration for a clinical trial of CKBA cream in children aged 2 to 12 with non-segmental vitiligo [1] Group 1 - The clinical trial is a multi-center, randomized, double-blind, placebo-controlled Phase II study [1] - The study will evaluate the safety, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrowband ultraviolet B (NB-UVB) therapy [1] - The trial specifically targets participants who are children aged 2 years and older [1]